ANIX

SEC Filing Summary: CopyTele, Inc. (10-Q)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended July 31, 1997, for CopyTele, Inc. (Note: The request metadata referenced "Anixa Biosciences," but the provided filing text is for CopyTele, Inc.). The Company is a development-stage enterprise focused on creating multi-functional telecommunications products, specifically the MAGICOM(R) 2000, which utilizes its proprietary E-PAPER(TM) flat panel display technology. Operations include a 55% owned joint venture in China, Shanghai CopyTele Electronics Co., Ltd. (SCE), for product manufacturing.

Key Financial Metrics

Note: The filing does not provide gross margin data as no revenue has been recognized. Sales are deferred pending product enhancements and initial sales stage completion.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss for the nine months ended July 31, 1997, increased by approximately $1.0 million compared to the prior year period, driven by higher operating expenses.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses rose by approximately $1.1 million year-over-year. This increase was primarily due to higher compensation costs (marketing department staffing and scientific personnel), increased engineering supplies (training components and product samples), and higher marketing and travel costs.
• Joint Venture Loss: The Company's share of the loss from its Chinese joint venture (SCE) increased by $155,000 for the nine-month period, reflecting higher costs as SCE entered initial production stages.
• Interest Income: Interest income increased by approximately $276,000 year-over-year due to higher interest rates and increased funds available for investment.
• Liquidity: Cash and cash equivalents decreased by approximately $6.35 million during the nine-month period, primarily due to operating cash burn and capital expenditures.

Guidance, Outlook, and Risks

• Revenue Recognition: The Company continues to defer sales and gross profit for the MAGICOM(R) 2000 as it is in the initial sales stage. No assurance is given that significant revenues will be generated in the future.
• Liquidity Outlook: Management believes current funds are sufficient to maintain development efforts and meet capital contribution obligations through the first quarter of fiscal 2000, assuming continued salary waivers by senior executives.
• Capital Requirements: The Company anticipates needing additional funds for future joint venture participation and R&D. It must maintain a minimum of $4,000,000 in net tangible assets to comply with NASDAQ listing requirements.
• Risks: Key risks include the ability of SCE to produce sufficient quantities, pricing competitiveness, product obsolescence, and the success of marketing efforts in international territories. There is no assurance that the Company will generate profits.
• Subsequent Events: Director John E. Gillies passed away on August 27, 1997. Mr. George P. Larounis was elected as an interim Director on September 4, 1997.

Investor Verification Checklist

• Verify the timeline for recognizing revenue from MAGICOM(R) 2000 sales and the specific accounting treatment for deferred income.
• Confirm the status of the salary waivers by the Chairman, President, and senior personnel, as the liquidity runway depends on this assumption.
• Assess the production capacity and financial health of the Shanghai CopyTele Electronics Co., Ltd. (SCE) joint venture, which is currently generating losses.
• Monitor the Company's net tangible assets to ensure compliance with the $4,000,000 NASDAQ listing requirement.
• Review the progress of the proposed "Second Joint Venture" with SECC and the associated capital contribution requirements.